The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPM.L Regulatory News (MPM)

  • There is currently no data for MPM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Adjournment of GM & suspension of trading

21 Oct 2019 07:00

RNS Number : 4628Q
mporium Group PLC
21 October 2019
 

The information communicated in this announcement includes inside information for the purposes of Article 7 Regulation 596/2014.

 

Mporium Group plc

("Mporium", the "Company" or the "Group")

 

Statement re adjournment of GM & suspension of trading

 

Mporium announces that its directors have taken the difficult decision to seek an indefinite adjournment of the Company's forthcoming general meeting (as detailed in the Company's announcement of 30 September 2019) and to request a suspension in the trading of its shares on AIM in view of a critical uncertainty with regard to its financial position.

 

On 25 January 2019, the Company entered into a Strategic Collaboration Agreement with Allay (UK) Ltd ("Allay") pursuant to which the Company was appointed by Allay as the exclusive supplier to Allay of customers and leads for Allay's business in seeking redress for breaches of consumer regulation (particularly, payment protection insurance ("PPI")). As part of this arrangement, Allay paid Mporium for selected leads acquired from the Company's partners and the Company would in turn "pass through" these payments to its partners.

 

The Company understood until recently that the nature of the services provided by Mporium and Allay in these circumstances were exempt for VAT purposes but, following recent discussions with HM Revenue & Customs ("HMRC") and the Company's tax advisers, it is understood that this may not be the case. The Company has received advice that HMRC's position is informed by findings in recent unconnected VAT Tribunal cases that may be subject to further challenge but, as the Company is not a party to these disputes, there can be no certainty that these findings would indirectly favour the Company's position or their timing.

 

HMRC have not to date issued a formal notification to Mporium requiring payment and further submissions to HMRC are planned. The Company estimates that the potential liability, were it to arise, would be in the region of £3.5 million (in respect of transactions totalling approximately £18 million). The Company does not expect that it would have the resources to meet such a liability. In light of this and the associated uncertainty, the Company's directors have concluded that it would not be appropriate to finalise the fundraising described in the announcement of 30 September 2019.

 

As stated in that announcement, this fundraising was needed (amongst other things) to support the Group in meeting its short-term working capital requirements and that further external financial support was also expected to be needed in the next financial year. In the absence of this fundraising, and aside from the uncertainty with regard to the potential VAT liability described above, the directors believe they have no choice but to conclude that there is a fundamental uncertainty regarding the Company's ability to continue as a going concern. The Company is taking specialist advice on the most appropriate course of action in these circumstances.

 

The Company will provide an update as soon as possible.

 

Charles Pendred, chairman of the Company commented: "It is extremely frustrating that this matter has arisen so unexpectedly at a time when the forward vision for the Company looked so promising. The leadership of the Company has changed, the cost base had been substantially reduced, the new strategy with its complementary acquisition was being implemented and current trading was encouraging. The lead generation business with Allay had also ceased. The Board are deeply upset at this outcome and every effort has been, and is being made, to find a solution."

 

 

Enquiries

 

Mporium:

020 3841 8411

Tom Smith, Chief Executive Officer

 

 

 

finnCap (NOMAD / joint broker)

020 7220 0500

Henrik Persson / Anthony Adams (Corporate Finance)

Andrew Burdis (Corporate Broking)

 

 

Novum Securities Limited (joint broker)

020 7399 9427

Colin Rowbury (Corporate Broking)

 

 

 

Yellow Jersey PR:

020 3004 9512

Joseph Burgess

 

 

 

 

About Mporium Group PLC

Mporium is a software company delivering high performance advertising campaigns through its proprietary technology platform, IMPACT. Mporium delivers automation and innovation to the advertising industry and the IMPACT platform enables customers to identify and leverage moments when there are significant changes in the levels of consumer engagement. Advertisers using the platform can optimise their campaigns through event-driven marketing, targeting audiences at the exact moments when consumer interest is at its highest. Further information can be found at www.mporium.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCPGGACUUPBGRU
Date   Source Headline
27th Jun 20087:00 amRNSAHS Meeting
25th Jun 200810:28 amRNSDirector/PDMR Shareholding
24th Jun 200810:23 amRNSResult of Annual General Meet
24th Jun 20087:00 amRNSAGM Statement
16th Jun 20087:30 amRNSTEMPUS study fully enrolled
4th Jun 20087:00 amRNSAnnual Report and Accounts
2nd Jun 20087:00 amRNSUS Marketing Consultant
22nd May 20087:00 amRNSPreliminary Results
12th Mar 20087:00 amRNSAura trial fully enrolled
5th Feb 20087:00 amRNSTEMPUS Trial Update
3rd Dec 20077:00 amRNSInterim Results
16th Oct 20077:00 amRNSTEMPUS trial starts in US
4th Oct 200711:06 amRNSChange of Registered Office
28th Sep 200711:32 amRNSDirector/PDMR Shareholding
17th Aug 20077:00 amRNSAIM Rule 26
16th Jul 200711:29 amRNSResult of AGM
16th Jul 20077:00 amRNSAGM Statement
2nd Jul 20074:13 pmRNSHolding(s) in Company
27th Jun 20077:01 amRNSIHS Scientific Meeting
21st Jun 20075:05 pmRNSAnnual Report and Accounts
13th Jun 20077:02 amRNSPreliminary Results
7th Jun 20077:02 amRNSAHS Scientific Meeting
1st Jun 20078:30 amRNSTotal Voting Rights
18th May 20079:20 amRNSAdditional Listing
30th Apr 20076:22 pmRNSHolding(s) in Company
30th Apr 200712:16 pmRNSTotal Voting Rights
11th Apr 20074:39 pmRNSConversion of Loan Note
2nd Apr 20073:27 pmRNSHolding(s) in Company
2nd Apr 20072:55 pmRNSHolding(s) in Company
2nd Apr 20071:26 pmRNSDirector/PDMR Shareholding
30th Mar 20079:32 amRNSTotal Voting Rights
27th Mar 20077:01 amRNSBoard Appointments
26th Mar 200710:31 amRNSResult of EGM
2nd Mar 20077:30 amRNSGPB17m fundraising
9th Jan 20077:01 amRNSPositive Tonabersat Study
20th Dec 20065:43 pmRNSTotal Voting Rights
1st Dec 20067:01 amRNSInterim Results
17th Nov 20067:01 amRNSPlacing
25th Oct 200610:20 amRNSResult of AGM
25th Oct 20067:01 amRNSAGM Statement
27th Sep 20067:00 amRNSNIH Collaboration
20th Sep 20067:02 amRNSPreliminary Results
7th Sep 20067:00 amRNSAdditional Indications
15th Aug 200611:37 amRNSNotification of Interests
20th Jun 20067:00 amRNSStart of Phase II Trial
24th May 20067:01 amRNSUCLA Collaboration
21st Mar 20067:00 amRNSStart of Phase II Trial
8th Mar 20067:03 amRNSChange of Adviser
13th Jan 20067:00 amPRNRe Agreement
8th Dec 20057:00 amPRNInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.